Searching…
d AK132, an asymmetric monovalent bispecific antibody, Claudin18.2 (CLDN18.2)/CD47, with a wild type IgG1 Fc. Claudin18. is a tight junction protein that has been identified as a valuable target in gastric and pancrea...
Upon administration of anti-CLDN18.2/CD47 bispecific antibody AK132, the anti-CLDN18.2 moiety selectively targets and binds to CLDN18.2 on CLDN18.2-expressing tumor cells, thereby improving the binding of the anti-CD4...
Nov 5, 2024 · To overcome these limitations and further improve therapeutic efficacy, we developed AK132, an asymmetric Claudin18.2 (CLDN18.2)/CD47 bispecific antibody with a wild type IgG1 Fc and with the monovalent ...
Dec 12, 2023 · This is A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor.
Nov 15, 2024 · AK132 is a bispecific antibody with a unique "1+1" valency that targets and blocks both CLDN18.2 and CD47. It incorporates a wild-type IgG1 Fc structure, and is currently undergoing clinical research.
Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting (PRNewswire) - "AK132 mediates macrophage phagocytosis of CLDN18.2+/CD47+ tumor cells and effect...
AK132 is a bispecific antibody developed by Akeso, targeting the recombinant humanized Claudin18.2 (CLDN18.2) splice variant 2 and CD47 for the treatment of various cancers, including gastric, esophageal, pancreatic, ...
